



Dehydroepiandrosterone Sulfate (DHEA-S) Test System
Product Code: 5175-300

1.0 INTRODUCTION

Intended Use: The Quantitative Determination of Dehydroepiandrosterone Sulfate Concentration (DHEA-S) in Human Serum or Plasma by a Microplate Enzyme Immunoassay, Chemiluminescence

2.0 SUMMARY AND EXPLANATION OF THE TEST

Dehydroepiandrosterone sulfate (DHEA-S) is the major C19 steroid secreted by the adrenal cortex, and is a precursor in testosterone and estrogen biosynthesis. DHEA-S, the sulfate ester of DHEA, is derived from sulfated precursors and by enzymatic conversion of DHEA in adrenal and extradrenal tissues. Due to the presence of a 17-oxo [rather than hydroxyl] group, DHEA-S possesses relatively weak androgenic activity, which for unsulfated DHEA has been estimated at ~10% that of testosterone.¹ However, the bioactivity of DHEA-S may be increased by its relatively high serum concentrations, approximately 100 to 1000-fold higher than DHEA or testosterone, and its weak affinity for sex-hormone binding globulin.²

The physiologic role of DHEA-S is not well-defined. Serum levels are relatively high in the fetus and neonate, low during childhood, and increase during puberty.^{3,4} Increased levels of DHEA-S during adrenarche may contribute to the development of secondary sexual hair. DHEA-S levels show a progressive decline after the third decade of life.⁵ Unlike DHEA, DHEA-S levels do not show significant diurnal variation and only show little day-to-day variation. DHEA-S levels are not responsive to acute corticotropin administration,⁴ and do not vary significantly during the normal menstrual cycle.² This may be due to the slower metabolic clearance rate of DHEA-S as compared to DHEA.⁶

Measurement of serum DHEA-S is a useful marker of adrenal androgen synthesis. Abnormally low levels have been reported in hypoadrenalism,³ while elevated levels occur in several conditions; including virilizing adrenal adenoma and carcinoma,⁷ 21-hydroxylase and 3β-hydroxysteroid dehydrogenase deficiencies^{2,6} and some cases of female hirsutism.² Since very little DHEA-S is produced by the gonads,^{2,3} measurement of DHEA-S may aid in the localization of the androgen source in virilizing conditions. Methods for measurement of DHEA-S include gas-liquid chromatography, double-isotope derivative techniques, competitive protein-binding assays, and radioimmunoassay. Although significant cross-reactivity occurs with DHEA, androstenedione and androsterone, the relative concentrations of these competing substances in most normal and pathologic samples predicts a minimal effect on assay performance.


The Monobind DHEA-S CLIA kit uses a specific anti-DHEA-S antibody, and does not require prior sample extraction of serum or plasma. Cross-reactivity to other naturally occurring and structurally related steroids is low. The employment of several serum references of known DHEA-S concentration permits construction of a graph of activity (light) and concentration. From

comparison to the dose response curve, an unknown specimen's activity can be correlated with DHEA-S concentration.

3.0 PRINCIPLE

Competitive Enzyme Immunoassay (TYPE 7):

The essential reagents required for an enzyme immunoassay include antibody, enzyme-antigen conjugate and native antigen. Upon mixing biotinylated antibody, enzyme-antigen conjugate and a serum containing the native antigen, a competition reaction results between the native antigen and the enzyme-antigen conjugate for a limited number of antibody binding sites. The interaction is illustrated by the following equation:



Ab_{Bn} = Biotinylated x-DHEA-S IgG Antibody (Constant Quantity)
Ag = Native Antigen (Variable Quantity)
Enz^{Ag} = Enzyme-antigen Conjugate (Constant Quantity)
AgAb_{Bn} = Antigen-Antibody Complex
Enz^{Ag}Ab_{Bn} = Enzyme-antigen Conjugate -Antibody Complex
k_a = Rate Constant of Association
k_{-a} = Rate Constant of Disassociation
K = k_a / k_{-a} = Equilibrium Constant

A simultaneous reaction between the biotin attached to the antibody and the streptavidin immobilized on the microwell occurs. This effects the separation of the antibody bound fraction after decantation or aspiration.

AgAb_{Bn} + Enz^{Ag}Ab_{Bn} + Streptavidin_{CW} ⇒ immobilized complex
Streptavidin_{CW} = Streptavidin immobilized on well
Immobilized complex = sandwich complex bound to the solid surface

The enzyme activity in the antibody bound fraction is inversely proportional to the native antigen concentration. By utilizing several different serum references of known antigen concentration, a dose response curve can be generated from which the antigen concentration of an unknown can be ascertained.

4.0 REAGENTS

A. DHEA-s Calibrators – 1 ml/vial - Icons A-F

Six (6) vials of serum reference for DHEA-S at concentrations of 0 (A), 0.2 (B), 1.0 (C), 2.0 (D), 4.0 (E) and 8.0 (F) in µg/ml. Store at 2-8°C. A preservative has been added. The calibrators can be expressed in molar concentrations (nM/L) by using 2.71 as the conversion.
For example: 1 µg/ml x 2.71 = 2.71 µM/L

B. DHEA-S Tracer Reagent – 6.0 ml/vial – Icon E

One (1) vial contains DHEA-S (Analog)-horseradish peroxidase (HRP) conjugate in a protein-stabilizing matrix with red dye. Store at 2-8°C.

C. DHEA-S Biotin Reagent – 6.0 ml/vial - Icon V

One (1) bottle of reagent contains anti-DHEA-S biotinylated purified rabbit IgG conjugate in buffer, blue dye and preservative. Store at 2-8°C.

D. Light Reaction Wells – 96 wells – Icon U

One 96-well white microplate coated with streptavidin and packaged in an aluminum bag with a drying agent. Store at 2-8°C.

E. Wash Solution – 20ml/vial – Icon U

One (1) vial contains surfactant in buffered saline. A preservative has been added. Store at 2-8°C.

F. Signal Reagent A – 7.0ml/vial - Icon C^A

One (1) vial contains luminol in a buffer. Store at 2-8°C.

G. Signal Reagent B – 7.0ml/vial - Icon C^B

One (1) vial contains hydrogen peroxide (H₂O₂) in buffer. Store at 2-8°C.

H. Product Insert.

Note 1: Do not use reagents beyond the kit expiration date.

Note 2: Avoid extended exposure to heat and light. **Opened reagents are stable for sixty (60) days when stored at 2-8°C. Kit and component stability are identified on the label.**

Note 3: Above reagents are for a single 96-well microplate.

4.1 Required But Not Provided:

1. Pipette capable of delivering 0.010ml (10µl) and 0.050ml (50µl) with a precision of better than 1.5%.

- Dispenser(s) for repetitive deliveries of 0.100ml (100µl) and 0.350ml (350µl) volumes with a precision of better than 1.5%.
- Adjustable volume (200-1000µl) dispenser(s) for conjugate.
- Microplate washer or a squeeze bottle (optional).
- Microplate Luminometer.
- Absorbent Paper for blotting the microplate wells.
- Plastic wrap or microplate cover for incubation steps.
- Vacuum aspirator (optional) for wash steps.
- Timer.
- Quality control materials.

5.0 PRECAUTIONS

For In Vitro Diagnostic Use
Not for Internal or External Use in Humans or Animals

All products that contain human serum have been found to be non-reactive for Hepatitis B Surface Antigen, HIV 1&2 and HCV Antibodies by FDA required tests. Since no known test can offer complete assurance that infectious agents are absent, all human serum products should be handled as potentially hazardous and capable of transmitting disease. Good laboratory procedures for handling blood products can be found in the Center for Disease Control / National Institute of Health, "Biosafety in Microbiological and Biomedical Laboratories," 2nd Edition, 1988, HHS Publication No. (CDC) 88-8395.

Safe Disposal of kit components must be according to local regulatory and statutory requirement.

6.0 SPECIMEN COLLECTION AND PREPARATION

The specimens shall be blood serum or heparinized plasma in type and taken with the usual precautions in the collection of venipuncture samples. The blood should be collected in a redtop (with or without gel additives) venipuncture tube or for plasma use evacuated tube(s) containing heparin. Allow the blood to clot for serum samples. Centrifuge the specimen to separate the serum or plasma from the cells.

In patients receiving therapy with high biotin doses (i.e. >5mg/day), no sample should be taken until at least 8 hours after the last biotin administration, preferably overnight to ensure fasting sample.

Samples may be refrigerated at 2-8°C for a maximum period of five (5) days. If the specimen(s) cannot be assayed within this time, the sample(s) may be stored at temperatures of -20°C for up to 30 days. Avoid use of contaminated devices. Avoid repetitive freezing and thawing. When assayed in duplicate, 0.020ml (20µl) of the specimen is required.

7.0 QUALITY CONTROL

Each laboratory should assay controls at levels in the low, normal and high range for monitoring assay performance. These controls should be treated as unknowns and values determined in every test procedure performed. Quality control charts should be maintained to follow the performance of the supplied reagents. Pertinent statistical methods should be employed to ascertain trends. The individual laboratory should set acceptable assay performance limits. In addition, maximum absorbance should be consistent with past experience. Significant deviation from established performance can indicate unnoticed change in experimental conditions or degradation of kit reagents. Fresh reagents should be used to determine the reason for the variations.

8.0 REAGENT PREPARATION

- Wash Buffer**
Dilute contents of Wash Concentrate to 1000ml with distilled or deionized water in a suitable storage container. Store diluted buffer at room temperature 20-27°C for up to 60 days.
- Working Signal Reagent Solution - Store at 2 - 8°C.**
Determine the amount of reagent needed and prepare by mixing equal portions of Signal Reagent A and Signal Reagent B in a clean container. For example, add 1 ml of A and 1 ml of B per two (2) eight well strips (A slight excess of solution is made). **Discard the unused portion if not used within 36 hours after mixing.** If complete utilization of the reagents is anticipated, within the above time constraint, pour the contents

of Signal Reagent B into Signal Reagent A and label accordingly.

9.0 TEST PROCEDURE

Before proceeding with the assay, bring all reagents, serum reference calibrators and controls to room temperature (20-27°C).
****Test Procedure should be performed by a skilled individual or trained professional****

- Format the microplates' wells for each serum reference, control and patient specimen to be assayed in duplicate. **Replace any unused microwell strips back into the aluminum bag, seal and store at 2-8°C.**
- Pipette 0.010 ml (10 µL) of the appropriate serum reference, control or specimen into the assigned well.
- Add 0.050 ml (50µl) of the DHEA-S Enzyme Tracer to all wells.
- Swirl the microplate gently for 20-30 seconds to mix.
- Add 0.050 ml (50µl) of Anti- DHEA-S Biotin Reagent to all wells.
- Swirl the microplate gently for 20-30 seconds to mix.
- Cover and incubate for 30 minutes at room temperature.
- Discard the contents of the microplate by decantation or aspiration. If decanting, blot the plate dry with absorbent paper.
- Add 0.3530ml (350µl) of wash buffer (see Reagent Preparation Section), decant (tap and blot) or aspirate. Repeat four (4) additional times for a total of five (5) washes. **An automatic or manual plate washer can be used. Follow the manufacturer's instruction for proper usage. If a squeeze bottle is employed, fill each well by depressing the container (avoiding air bubbles) to dispense the wash. Decant the wash and repeat four (4) additional times.**
- Add 0.100 ml (100µl) of working signal reagent solution to all wells (see Reagent Preparation Section). **Always add reagents in the same order to minimize reaction time differences between wells.**
DO NOT SHAKE THE PLATE AFTER SIGNAL ADDITION
- Incubate at room temperature for five (5) minutes in the dark.
- Read the relative light units in each well with a Chemiluminescence microplate reader for 0.5-1.0 seconds. **The results should be read within 30 minutes after adding the working Signal Reagent.**

Note: Dilute the samples suspected of concentrations higher than 8.0 µg/ml 1:5 and 1:10 with DHEA-S '0' µg/ml calibrator or patient serum pools with a known low value for DHEA-S.

10.0 CALCULATION OF RESULTS


A dose response curve is used to ascertain the concentration of progesterone in unknown specimens.

- Record the RLUs obtained from the printout of the microplate reader as outlined in Example 1.
- Plot the RLUs for each duplicate serum reference versus the corresponding Progesterone concentration in ng/ml on linear graph paper.
- Draw the best-fit curve through the plotted points.
- To determine the concentration of DHEA-S for an unknown, locate the average RLUs for each unknown on the vertical axis of the graph, find the intersecting point on the curve, and read the concentration (in ng/ml) from the horizontal axis of the graph (the duplicates of the unknown may be averaged as indicated). In the following example, the average RLUs (12337) of the unknown intersects the calibration curve at 5.23 DHEA-S concentration (see Figure1).

Note: Computer data reduction software designed for CLIA Assays may also be used for the data reduction. **If such software is utilized, the validation of the software should be ascertained.**

EXAMPLE 1

Sample I.D.	Well Number	RLU (A)	Mean RLU (B)	Value (ng/ml)
Cal A	A1	99741	100000	0.0
	B1	100259		
Cal B	C1	63254	63767	0.2
	D1	64281		
Cal C	E1	37914	37829	1.0
	F1	37745		
Cal D	G1	26169	26621	2.0
	H1	27073		
Cal E	A2	15739	15518	4.0
	B2	15297		
Cal F	C2	8337	8549	8.0
	D2	8761		
Cont 1	G2	41973	42662	0.74
	H2	43351		
Pat# 1	A3	12410	12337	5.23
	B3	12264		



* The data presented in Example 1 and Figure 1 is for illustration only and **should not** be used in lieu of a dose response curve prepared with each assay. In addition, the RLUs of the calibrators have been normalized to 100,000 RLUs for the A calibrator (greatest light output). This conversion minimizes differences caused by efficiency of the various instruments that can be used to measure light output.

11.0 Q.C. PARAMETERS

In order for the assay results to be considered valid the following criteria should be met:

- The Dose Response Curve should be within established parameters.
- Four out of six quality control pools should be within the established ranges.

12.0 RISK ANALYSIS

The MSDS and Risk Analysis Form for this product is available on request from Monobind Inc.

12.1 Assay Performance

- It is important that the time of reaction in each well is held constant to achieve reproducible results.
- Pipetting of samples should not extend beyond ten (10) minutes to avoid assay drift.
- Highly lipemic, hemolyzed or grossly contaminated specimen(s) should not be used.
- If more than one (1) plate is used, it is recommended to repeat the dose response curve.
- The addition of signal reagent initiates a kinetic reaction, therefore the signal reagent(s) should be added in the same sequence to eliminate any time-deviation during reaction.
- Failure to remove adhering solution adequately in the aspiration or decantation wash step(s) may result in poor replication and spurious results.
- Use components from the same lot. No intermixing of reagents from different batches.
- Patient specimens with DHEA-S concentrations above 8.0 µg/ml may be diluted (1/5, 1/10 or higher) with DHEA-S '0' calibrator and re-assayed. The sample's concentration is obtained by multiplying the result by the dilution factor.
- Accurate and precise pipetting, as well as following the exact time and temperature requirements prescribed are essential. Any deviation from Monobind IFU may yield inaccurate results.
- All applicable national standards, regulations and laws, including, but not limited to, good laboratory procedures, must

be strictly followed to ensure compliance and proper device usage.

- It is important to calibrate all the equipment e.g. Pipettes, Readers, Washers and/or the automated instruments used with this device, and to perform routine preventative maintenance.
- Risk Analysis- as required by CE Mark IVD Directive 98/79/EC - for this and other devices, made by Monobind, can be requested via email from Monobind@monobind.com.

12.2 Interpretation

- Measurements and interpretation of results must be performed by a skilled individual or trained professional.**
- Laboratory results alone are only one aspect for determining patient care and should not be the sole basis for therapy, particularly if the results conflict with other determinants.
- The reagents for the test system have been formulated to eliminate maximal interference; however, potential interaction between rare serum specimens and test reagents can cause erroneous results. Heterophilic antibodies often cause these interactions and have been known to be problems for all kinds of immunoassays (Boscato LM, Stuart MC. 'Heterophilic antibodies: a problem for all immunoassays' Clin. Chem. 1988:3427-33). For diagnostic purposes, the results from this assay should be in combination with clinical examination, patient history and all other clinical findings.
- For valid test results, adequate controls and other parameters must be within the listed ranges and assay requirements.
- If test kits are altered, such as by mixing parts of different kits, which could produce false test results, or if results are incorrectly interpreted, **Monobind shall have no liability.**
- If computer controlled data reduction is used to interpret the results of the test, it is imperative that the predicted values for the calibrators fall within 10% of the assigned concentrations.
- Clinically, a **DHEA-S value alone is not of diagnostic value** and should only be used in conjunction with other clinical manifestations (observations) and diagnostic procedures.

13.0 EXPECTED RANGES OF VALUES

In agreement with established reference intervals for a "normal" adult population, the expected ranges for the DHEA-S AccuLite® CLIA Test System are detailed in Table 1.

TABLE 1
Expected Values for the DHEA-S Test System (µg/ml)

Male	0.06 – 4.58
Female	0.03 – 5.88

It is important to keep in mind that establishment of a range of values which can be expected to be found by a given method for a population of "normal" persons is dependent upon a multiplicity of factors: the specificity of the method, the population tested and the precision of the method in the hands of the analyst. For these reasons each laboratory should depend upon the range of expected values established by the manufacturer only until an in-house range can be determined by the analysts using the method with a population indigenous to the area in which the laboratory is located.

14.0 PERFORMANCE CHARACTERISTICS

14.1 Precision

The within and between assay precision of the DHEA-S AccuLite® CLIA Test System were determined by analyses on three different levels of pool control sera. The number, mean values, standard deviation and coefficient of variation for each of these control sera are presented in Table 2 and Table 3.

TABLE 2
Within Assay Precision (Values in µg/ml)

Sample	N	X	σ	C.V.
Low	16	0.66	0.06	9.8%
Normal	16	1.14	0.05	4.9%
High	16	4.84	0.21	4.3%

TABLE 3
Between Assay Precision (Values in µg/ml)

Sample	N	X	σ	C.V.
Low	10	0.61	0.06	9.5%
Normal	10	1.36	0.04	3.1%
High	10	4.73	0.16	3.4%

*As measured in ten experiments in duplicate over a ten day period.

14.2 Sensitivity

The DHEA-S AccuLite® CLIA Test System has a sensitivity of 0.09 µg/ml. The sensitivity was ascertained by determining the variability of the 0 µg/ml serum calibrator and using the 2σ (95% certainty) statistic to calculate the minimum dose.

14.3 Accuracy

The DHEA-S AccuLite® CLIA Test System was compared with a chemiluminescence immunoassay method. Biological specimens from low, normal and relatively high DHEA-S level populations were used (The values ranged from 0.2 µg/ml – 7.7 µg/ml). The total number of such specimens was 77. The least square regression equation and the correlation coefficient were computed for this DHEA-S CLIA in comparison with the reference method. The data obtained is displayed in Table 4.

TABLE 4

Method	Mean (x)	Least Square Regression Analysis	Correlation Coefficient
Monobind (y)	1.12	y=0.1448+0.9858(X)	0.983
Reference (x)	1.18		

Only slight amounts of bias between this method and the reference method are indicated by the closeness of the mean values. The least square regression equation and correlation coefficient indicates excellent method agreement.

14.4. Specificity

The % cross reactivity of the DHEA-S antibody to selected substances was evaluated by adding the interfering substance to a serum matrix at various concentrations. The cross-reactivity was calculated by deriving a ratio between dose of interfering substance to dose of DHEA-S needed to displace the same amount of labeled analog.

Substance	Cross Reactivity
DHEA-S	1.0000
DHEA	0.0004
Androstenedione	0.0003
Dihydrotestosterone	0.0008
Cortisone	<0.0001
Corticosterone	<0.0001
Cortisol	0.0004
Spirolactone	<0.0001
Estrinol	<0.0001
Estradiol	<0.0001
Estrone	<0.0001
Testosterone	<0.0001

15.0 REFERENCES

- Dorfman RI, Shipley RA: *Androgens*, John Wiley and Sons, New York, 1956, pp. 116-128.
- Pang S, Riddick L: Hirsutism. IN Lifshitz F (Ed): *Pediatric Endocrinology*, A Clinical Guide, second edition. Marcel Dekker, Inc., New York, 1990, pp. 259-291.
- De Peretti E, Forest MG: Pattern of plasma dehydroepiandrosterone sulfate levels in humans from birth to adulthood: evidence for testicular production. *J Clin Endocrinol Metab*, 47:572-577 (1978).
- Lashansky G, Saenger P, Fishman K, Gautier T, Mayes D, Berg G, Di Martino-Nardi J, Reiter E, "Normative data for adrenal steroidogenesis in a healthy pediatric population: age and sex-related changes after adrenocorticotropic stimulation", *J Clin Endocrinol Metab*, 73:674-686 (1991).
- Zumoff B, Roenfeld RS, Stain GW, Levin J, Fukushima DK," Sex differences in twenty-four hour mean plasma concentration of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) and the DHEA to DHEAS ratio in normal adults", *J Clin Endocrinol Metab* 51:330-333 (1980).
- Pang S, Lerner A, Stoner E, Oberfield S, Engle I, New M, "Late-onset adrenal steroid 3'-hydroxysteroid dehydrogenase deficiency: A cause of hirsutism in pubertal and postpubertal women", *J Clin Endocrinol Metab*, 60:428-439 (1985).
- Lee PDK, Winter RJ, and Green OC, "Virilizing adrenocortical tumors in childhood: eight cases and a review of the literature", *Pediatrics*, 76:437-444 (1985).

- Rittmaster RS, "Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide" *J Clin Endocrinol Metab*, 67:651-655,(1988).
- Beer NA, Jakubowicz DJ, Beer RM, Arocha IR, and Nestler JE "Effects of nintredipine on glucose tolerance and serum insulin dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men", *J Clin Endocrinol Metab*, 76:178-163 (1993).
- Tietz, NW, *Textbook of clinical chemistry*, 2nd ed. Philadelphia: W.B. Saunders, 1994.

Revision: 5 Date: 2019-Jul-16 DCO: 1353
MP5175 Product Code: 5175-300

Size	96 (A)		192 (B)	
	Reagent (fill)	A)	1ml set	B)
	B)	1 (6ml)	C)	2 (6ml)
	C)	1 (6ml)	D)	2 (6ml)
	D)	1 plate	E)	1 (20ml)
	E)	1 (20ml)	F)	1 (20ml)
	F)	1 (7ml)	G)	2 (7ml)
	G)	1 (7ml)		2 (7ml)

For Orders and Inquires, please contact



Tel: +1 949.951.2865 Mail: info@monobind.com
Fax: +1 949.951.3539 Fax: www.monobind.com



Please visit our website to learn more about our products and services.

Glossary of Symbols
(EN 980/ISO 15223)

